Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dovato versus Biktarvy as first-line treatment in antiretroviral-naive adults with HIV-1
2023-504993-40-00Phase 3Authorised
- Sponsor
- ViiV Healthcare
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, open-label trial in Human immunodeficiency virus infection type 1 comparing Dovato arm with Biktarvy arm (2 arms). Primary endpoint: Virologic suppression at Week 48. Planned start Feb 2024; status: authorised.
02
Drugs
dolutegravir + lamivudinebictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2023-504993-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504993-40-00.